Indivior
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Virginia, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
10710 Midlothian Tpke Ste 125, Richmond,...Phone Number
(804) 379-1090Website
www.indivior.comRevenue
$1.3 BillionStock Symbol
INDVIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
6
1
2
2
2
1
About Indivior
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The companys product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia. It markets and promotes SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company was incorporated in 2014 and is headquartered in Richmond,...Explore more
Indivior Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Indivior your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Indivior has new funding data
Website visits: Recent activity has been detected on your website
Indivior, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Indivior is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Indivior
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Indivior had a recent Job posting/layoffs
Check if Indivior has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Indivior launches new products
Earning: See what the market has to say on Indivior recently announced quarterly report
Recommended Actions
Find VP level buyers at Indivior
Find more new buyers
Compare Similar Companies to Indivior
Compare insights from companies similar to Indivior, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Indivior is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Indivior is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Indivior.
Indivior Tech Stack
A closer look at the technologies used by Indivior
See more technologies
Most Recent Scoops
Open Position
Project
Indivior has executed a $175 million accelerated share repurchase program as part of its capital allocation strategy, citing a meaningful disconnect between the company's intrinsic value and its current share price.
Spending/Investment, Share Placement, Finance
Project
Indivior has established acquisition criteria requiring targets to have over $200 million in peak sales potential, with deals expected to be accretive in the year of closing or the following year, and the company has indicated comfort with leverage of up to three times as part of its business development strategy.
Business Development, Acquisitions
Project
anticipates entering phase three of its action agenda, the "Breakout" phase, in the second half of the year, with a focus on enhancing and diversifying the company's growth profile through commercial-stage acquisitions.
Acquisitions, Corporate Strategy
Project
CRM, Advertising, Marketing Campaign, Pharmaceuticals, Communications, Marketing Communications
Indivior News & Media
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%
Indivior develops buprenorphine-based therapies for opioid dependence, serving healthcare providers and treatment centers worldwide.New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse risk, fewer infection-related complications, and reduced healthcare utilization among people living with opioid use disorder (OUD). “Collectively, these studies highlight the benefits of suIndivior to Participate in Upcoming Investor Conferences
RICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences:Indivior Announces $175 Million Accelerated Share Repurchase
RICHMOND, Va., May 04, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced that it has entered into a $175 million accelerated share repurchase agreement (“the ASR”) with Barclays Bank PLC (“Barclays”). The ASR will be executed under Indivior’s existing $400 million share repurchase program previously authorized by the Company’s Board of Directors. The ASR reflects the Company’s confidence in its long-term strategy, cash flow generation, and commitment to disc
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Indivior
Sign Up For FreeTo access detailed company insights
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The companys product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia. It markets and promotes SUBOXONE subli... Read More
